Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WXD171-TraP
- Development stage
- Preclinical
- Lead developer
- Kaken Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
WXD171-TraP is an experimental oral vaccine candidate utilizing an engineered probiotic strain, *Limosilactobacillus reuteri* WXD171, as a delivery vehicle for the *Staphylococcus aureus* antigen TraP (Target of RNAIII-activating protein). It is designed to elicit mucosal and systemic immune responses to protect against *S. aureus* infections, including pneumonia and sepsis. The vaccine platform leverages the natural ability of *L. reuteri* to survive the gastrointestinal environment and adhere to the intestinal mucosa, thereby facilitating the presentation of the TraP antigen to gut-associated lymphoid tissues (GALT). In preclinical studies, this live vaccination strategy has been evaluated alongside other antigen-specific constructs like WXD171-IsdB to determine its efficacy in inducing protective immunity against nosocomial and community-acquired infections.
- Other names
- Limosilactobacillus reuteri WXD171-TraPengineered L. reuteri WXD171-TraP
02
Targets
LRPAP1 (LRP-associated protein 1)
Beyond the preview
Go deeper on WXD171-TraP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WXD171-TraP.